Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

RBC Capital Reiterates Outperform on Varonis Systems, Maintains $31 Price Target

RBC Capital analyst Matthew Hedberg reiterates Varonis Systems (NASDAQ:VRNS) with a Outperform and maintains $31 price target.
byBenzinga Newsdesk
March 15, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

RBC Capital analyst Matthew Hedberg reiterates Varonis Systems (NASDAQ:VRNS) with a Outperform and maintains $31 price target.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Bristol Myers Squibb Provides Update On RELATIVITY-123 Trial Evaluating The Fixed-Dose Combination Of Nivolumab And Relatlimab In Patients With Previously Treated Metastatic Microsatellite Stable Colorectal Cancer

By Happy Mohamed
December 16, 7:37 PM
Bristol Myers Squibb (NYSE:BMY) today announced that the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab for the treatment of microsatellite stable (MSS) metastatic

BMY